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Key questions
What is already known about this subject?
 ► Ticagrelor and prasugrel have both been shown to 
be beneficial when used in patients with acute cor-
onary syndromes. However, there is little available 
data to guide clinicians in choosing between these 
newer agents in primary percutaneous coronary in-
tervention (PPCI).
What does this study add?
 ► The main finding of this study was that prasugrel 
was associated with lower risk-adjusted mortality 
compared with both clopidogrel and ticagrelor, in 
patients undergoing PPCI. Both prasugrel and tica-
grelor were associated with lower recurrent myo-
cardial infarction compared with clopidogrel. There 
were no significant differences in bleeding among 
the three groups.
How might this impact on clinical practice?
 ► The findings of this study suggest that the use of 
prasugrel and ticagrelor in PPCI could lead to im-
proved outcomes compared with clopidogrel. The 
difference in outcomes noted between prasugrel 
and ticagrelor may influence prescribing choice in 
selected patients, until further data are published 
from randomised controlled trials.
AbstrAct
Background There is a paucity of real-world outcome 
data comparing clopidogrel, prasugrel and ticagrelor in 
primary percutaneous coronary intervention (PPCI) for 
ST-segment elevation myocardial infarction (STEMI). We 
sought to assess the association of choice of oral P2Y12-
receptor inhibitor with clinical outcomes following PPCI for 
STEMI in a large consecutive patient series.
Methods Demographic, procedural and 12-month 
outcome data were prospectively collected for all patients 
undergoing PPCI in Leeds, UK, between 01 January 2009 
and 31 December 2011, and 01 January 2013 and 31 
December 2013. Clinical endpoints were 30-day and 
12-month all-cause mortality, recurrent MI and 30-day 
HORIZONS-major bleeding. Logistic regression analyses 
were undertaken to adjust for confounding factors.
Results Prasugrel (n=1244) was associated with lower 
adjusted 30-day (OR 0.53 (0.34–0.85)) and 12-month 
(OR 0.55 (0.38–0.78)) mortality, and 12-month MI (OR 
0.63 (0.42–0.94)) compared with clopidogrel (n=1648). 
Importantly, prasugrel was associated with lower adjusted 
30-day mortality (OR 0.51 (0.29–0.91)) compared with 
ticagrelor (n=811). Lower 30-day (OR 0.40 (0.17–0.94)) 
and 12-month (OR 0.54 (0.32–0.93)) MI were observed 
in ticagrelor compared with clopidogrel, an association 
absent in comparison with prasugrel. Adjusted bleeding 
were not statistically significantly different among the 
P2Y12-receptor inhibitors.
Conclusion In this large consecutive real-world series, 
prasugrel was associated with lower adjusted 30-day 
mortality compared with ticagrelor and clopidogrel, 
and lower adjusted 12-month mortality compared with 
clopidogrel. Both prasugrel and ticagrelor were associated 
with lower recurrent MI following PPCI compared with 
clopidogrel, with no overall increase in adjusted bleeding.
IntRoduCtIon
Primary percutaneous coronary intervention 
(PPCI) is the guideline-recommended treat-
ment strategy for patients presenting with 
ST-segment elevation myocardial infarction 
(STEMI).1 2
The addition of oral platelet P2Y12 ADP 
receptor inhibitors to aspirin has been 
shown to significantly reduce adverse events 
following PCI.3–6 Therefore, dual-antiplatelet 
therapy (DAPT) in PPCI for STEMI has been 
recommended for use periprocedurally and 
postprocedurally up to a minimum of 12 
months.1 2 7 Despite evidence of significant 
difference in platelet reactivity in patients 
treated with prasugrel compared with tica-
grelor, there have been only two observational 
studies and one meta-analysis comparing 
clinical outcomes of patients treated with 
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prasugrel with clinical outcomes of patients treated with 
ticagrelor in STEMI, with contrasting results.8–11 In terms 
of randomised controlled trials (RCTs), the PRAGUE-18 
study which aimed to compare prasugrel with ticagrelor 
was terminated early due to futility and ISAR-REACT 5 is 
still ongoing.12 13
The aim of this prospective outcomes study was to 
obtain ‘real-world’ data from a large consecutive patient 
series, to facilitate comparison of clinical outcomes of 
patients treated with clopidogrel, prasugrel and tica-
grelor when undergoing PPCI.
MetHods
The West Yorkshire PPCI Outcome Study was estab-
lished as a prospective, observational study to ascertain 
procedural and demographic characteristics, and clinical 
outcomes in all patients undergoing PPCI for STEMI at 
Leeds General Infirmary (LGI), UK. LGI is the largest 
single-centre PPCI centre by volume in the UK, providing 
a 24/7 PPCI service to a catchment population of 3.2 
million people. The period of recruitment was from 1st 
of January 2009 until 31st of December 2011, and 1st of 
January 2013 until 31st of December 2013 (4 calendar 
years). Patients who presented between 01 January 2012 
and 31 December 2012 were not included as follow-up, 
and data input were not possible due to limited staff avail-
ability at the time.
Primary endpoints were 30-day and 12-month all-cause 
mortality. Secondary endpoints were 30-day and 12-month 
MI, and 30-day major bleeding by HORIZONS criteria14 
(defined as intracranial or intraocular bleeding; access 
site bleeding of diameter of ≥5 cm, or requiring inter-
vention; a reduction in haemoglobin of ≥40 g/L without 
an overt source of bleeding, or ≥30 g/L with an overt 
source of bleeding; re-operation for bleeding and blood 
transfusion).
Patients who presented with chest pain consistent 
with myocardial ischaemia for a minimum of 20 min 
with ST-segment elevation of ≥1 mm in contiguous limb 
leads and/or ≥2 mm in contiguous chest leads, or with 
presumed new left bundle branch block on a 12-lead 
ECG were diagnosed with STEMI and were included 
in this study. Patients were transferred by paramedics 
directly to the cardiac catheter laboratories in LGI after 
first medical contact, with a telephone referral en route 
to minimise prehospital delays.15 Emergency diagnostic 
coronary angiography with (if indicated) follow-on PPCI 
was undertaken if patients presented within 12 hours of 
symptom onset. Oral aspirin 300 mg (administered at 
the point of diagnosis usually in the prehospital setting) 
and either 600 mg clopidogrel, 60 mg prasugrel or 180 
mg oral ticagrelor (administered in the cardiac catheter-
isation laboratory prior to PPCI, with the exception of 
patients who were referred from surrounding emergency 
departments, who received their P2Y12-receptor inhib-
itor prior to transfer to the cardiac catheterisation labo-
ratories) were administered preprocedure, depending 
on guideline recommendations at the time of index 
PPCI. Either bivalirudin or unfractionated heparin (±bail 
out glycoprotein IIb/IIIa inhibitor) were administered 
during PPCI. Arterial access site, choice of stent (drug-
eluting stent (DES) or bare-metal stent (BMS)) and 
aspiration thrombectomy were at the operator’s discre-
tion. Thrombolysis in MI (TIMI) classification was used 
to grade preprocedure and postprocedure flow in the 
infarct-related artery. Call-for-help time (call time) and 
time of patient arrival at LGI (door time) were obtained 
either from the ambulance reports or if patients self-pre-
sented from the emergency department triage notes. 
Time to first interventional device (balloon time) was 
obtained from the electronic cardiac catheter laboratory 
report. Patients were observed on the coronary care unit 
post-PPCI for a minimum of 24 hours, and remained in 
the hospital for a minimum of 72 hours (either at LGI if 
patients were local, or re-patriated to the nearest district 
general hospital after a minimum of 6 hours observa-
tion). DAPT, statin therapy, beta-adrenergic receptor 
blockers, ACE inhibitors (or angiotensin II receptor 
blockers) and (if indicated) mineralocorticoid receptor 
antagonists were prescribed according to guideline 
recommendation.
Follow-up
Written and electronic case notes were reviewed at 
the time of discharge to ascertain patient character-
istics, procedural variables and in-hospital outcomes. 
Drug therapy and adverse events were identified up to 
a minimum of 12 months following index PPCI by a 
combination of patient telephone contact, accessing 
clinical information via written or electronic hospital 
records or from the responsible primary care physician. 
Mortality data up to a minimum of 12 months post-PPCI 
were obtained from the Office of National Statistics and 
central National Health Service (NHS) records. The 
Myocardial Infarction National Audit Project (MINAP) 
database (database with information pertaining to all 
patients admitted acutely into NHS hospitals in England 
and Wales with unstable angina, non-STEMI and STEMI) 
was used to identify MIs. Review of hospital discharge and 
clinic letters, and hospital electronic pathology servers 
(for a rise in creatine kinase and/or troponin, and drops 
in haemoglobin) were undertaken to verify MIs and 
bleeding. Event adjudication was undertaken by blinded 
clinicians in consensus.
statistical analysis
Data checking and validation were undertaken to 
ensure the accuracy and validity of values obtained, 
and summary statistics were generated. All analyses 
were performed in IBM SPSS V.23.0.0.2. Records with 
incomplete data collection were excluded from the anal-
yses. Results were analysed according to P2Y12-receptor 
inhibitor treatment at LGI. Continuous variables were 
reported as medians with their corresponding IQR. Cate-
gorical variables were reported as frequencies with their 
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corresponding percentages (n (%)). Categorical variables 
were compared using χ2 tests. Continuous variables were 
compared using independent samples Student’s t-tests 
and Mann-Whitney U tests, as appropriate. A two-sided p 
value of ≤0.05 was considered statistically significant.
Multivariable logistic regression was used to correct 
for confounding variables, and all ORs from the logistic 
regression models were reported with 95% CIs. Variables 
included in the logistic regression models were: P2Y12-re-
ceptor inhibitor, diabetes mellitus, hypertension, hyper-
cholesterolaemia, renal dysfunction, prior MI, anterior 
MI, peripheral vascular disease or cerebrovascular disease, 
age above 65 years, radial artery access, call-to-balloon 
time of above 120 min, glycoprotein IIb/IIIa antagonist 
use, presentation with cardiogenic shock, year PPCI was 
performed and DES implantation. These variables were 
selected as known confounders, and exploratory analyses 
revealed that all of them had p values of ≤0.10.
Results
A total of 4056 patients underwent PPCI during the 
recruitment period. Baseline, clinical and follow-up 
data were available for 3703 (91.3%) patients who were 
included in the analysis. Data for 30-day and 12-month 
mortality, as well as 30-day and 12-month MI, were avail-
able for all included patients. Data for 30-day bleeding 
were available for 3449 (93.1%) of the 3703 patients, who 
were included in the analysis.
A total of 1648 (44.5%) patients received clopido-
grel, 1244 (33.6%) patients received prasugrel and 811 
(21.9%) patients received ticagrelor as their P2Y12-re-
ceptor inhibitor. There were multiple statistically signif-
icant differences in baseline and procedural variables 
(table 1). The temporal trends of use of each P2Y12-re-
ceptor inhibitor over the study period are shown in 
figure 1. Unadjusted and adjusted rates of 30-day and 
12-month mortality, recurrent MI and 30-day bleeding 
are listed in table 2.
Prasugrel versus ticagrelor
Statistically significant differences in unadjusted and 
adjusted 30-day mortality were observed in the compar-
ison of prasugrel with ticagrelor, favouring patients 
receiving prasugrel. Although unadjusted 12-month 
mortality was lower in patients receiving prasugrel, multi-
variable analysis revealed no statistically significant differ-
ence in adjusted 12-month mortality between the two 
groups. Unadjusted and adjusted 30-day bleeding were 
not statistically significantly different between the two 
groups either (table 2).
Prasugrel versus clopidogrel
Comparison of prasugrel and clopidogrel revealed statis-
tically significant differences in unadjusted and adjusted 
mortality, both at 30 days and 12 months, with both 
endpoints being statistically significantly lower in patients 
receiving prasugrel, compared with patients receiving 
clopidogrel. Unadjusted and adjusted 30-day MI, and 
adjusted 12-month MI were statistically significantly lower 
in patients receiving prasugrel compared with clopi-
dogrel. Unadjusted and adjusted rates of 30-day bleeding 
were not statistically significantly different between the 
two groups (table 2).
ticagrelor versus clopidogrel
Unadjusted and adjusted 30-day and 12-month mortality, 
and 30-day major bleeding were not statistically signifi-
cantly different between the two groups. However, unad-
justed and adjusted 30-day and 12-month MI were statis-
tically significantly less likely in patients receiving ticagr-
elor compared with clopidogrel (table 2).
dIsCussIon
Our analysis of real-world data from a large consecu-
tive patient series from a UK tertiary cardiac centre has 
provided an important head-to-head clinical comparison 
between prasugrel and ticagrelor in the setting of PPCI 
for STEMI, with the first direct comparison of bleeding 
between ticagrelor and prasugrel. We have also compared 
prasugrel and ticagrelor individually with clopidogrel. 
Patients treated with prasugrel in this series were found 
to have a statistically significantly lower adjusted 30-day 
and 12-month mortality compared with those treated 
with clopidogrel, a finding which was not observed in 
the ticagrelor cohort compared with clopidogrel. Impor-
tantly, we have shown for the first time that patients 
receiving prasugrel had lower adjusted 30-day mortality 
compared with ticagrelor, a finding which approached, 
but did not reach statistical significance at 12 months 
(p=0.06). Both prasugrel and ticagrelor were associated 
with lower adjusted MI compared with clopidogrel, with 
ticagrelor being statistically significantly different at both 
30 days and 12 months. We did not observe any differ-
ence in adjusted bleeding among the three P2Y12-re-
ceptor inhibitors.
Olier et al compared survival of >89 000 patients 
according to P2Y12-receptor inhibitor therapy, and 
found that in patients undergoing PPCI, treatment with 
prasugrel was associated with lower mortality compared 
with ticagrelor or clopidogrel, with no significant differ-
ence observed between ticagrelor and clopidogrel.10 
The main finding in our study, that prasugrel use was 
associated with better outcomes compared with tica-
grelor and clopidogrel, was in keeping with their results. 
Contrary to RCT findings, their study found that in-hos-
pital bleeding was significantly lower with prasugrel and 
ticagrelor compared with clopidogrel, despite prior 
studies suggesting that the third-generation P2Y12-re-
ceptor inhibitors were more potent at platelet inhibition. 
However, in addition to mortality, our study compared 
rates of recurrent MI and 30-day bleeding, which are both 
important factors to consider in comparisons of P2Y12-re-
ceptor inhibitor therapy.
In comparison to the analysis by Gosling et al,9 we did 
not observe a reduction in mortality in patients treated 
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Figure 1 P2Y12-receptor inhibitor administration over the 
study period.
Table 2 Comparison of clinical outcomes between P2Y12-receptor inhibitors
Clopidogrel vs ticagrelor Clopidogrel vs prasugrel Ticagrelor vs prasugrel
Clopidogrel 
(n=1648)
Ticagrelor
(n=811)
Clopidogrel 
(n=1648)
Prasugrel
(n=1244)
Ticagrelor
(n=811)
Prasugrel
(n=1244)
30-day outcomes
  Mortality, n (%)
  Adjusted OR (95% CI)
117 (7.0)
1.00
56 (6.9)
1.05 (0.61 to 1.80)
117 (7.0)
1.00
40 (3.2)*
0.53 (0.34 to 0.85)*
56 (6.9)
1.00
40 (3.2)*
0.51 (0.29 to 0.91)*
  MI, n (%)
  Adjusted OR (95% CI)
48 (2.9)
1.00
9 (1.1)*
0.40 (0.17 to 0.94)*
48 (2.9)
1.00
21 (1.7)*
0.58 (0.32 to 1.05)
9 (1.1)
1.00
21 (1.7)
1.44 (0.61 to 3.42)
  Major bleeding, n (%)
  Adjusted OR (95% CI)
95 (6.1)
1.00
37 (4.6)
0.98 (0.64 to 1.52)
95 (6.1)
1.00
52 (4.6)
1.05 (0.73 to 1.52)
37 (4.6)
1.00
52 (4.6)
1.07 (0.67 to 1.70)
12-month outcomes
  Mortality, n (%)
  Adjusted OR (95% CI)
193 (11.7)
1.00
77 (9.5)
0.84 (0.55 to 1.29)
193 (11.7)
1.00
68 (5.5)*
0.55 (0.38 to 0.78)*
77 (9.5)
1.00
68 (5.5)*
0.65 (0.41 to 1.02)
  MI, n (%)
  Adjusted OR (95% CI)
108 (6.6)
1.00
26 (3.2)*
0.54 (0.32 to 0.93)*
108 (6.6)
1.00
47 (3.8)*
0.63 (0.42 to 0.94)*
26 (3.2)
1.00
47 (3.8)
1.16 (0.67 to 2.01)
Data are expressed in n (%).
*P value≤0.05.
MI, myocardial infarction.
with ticagrelor compared with clopidogrel. We found 
that prasugrel was associated with reduced mortality at 
30 days and 12 months compared with clopidogrel, and 
at 30 days compared with ticagrelor, which was partly 
in keeping with their findings. In their study, although, 
30-day outcomes were not presented, a signal towards 
lower 12-month mortality in patients receiving prasu-
grel compared with ticagrelor was observed (HR 0.81 
(0.61–1.10)). Key differences in statistical analyses might 
account for the differences in findings. Gosling et al 
did not present or adjust for arterial access site, which 
could have been different between the groups if there 
was a temporal trend in the use of relevant P2Y12-re-
ceptor antagonist. Radial artery access was included in 
our regression models, and was found to be an inde-
pendent predictor of outcomes, with lower adjusted 
30-day (OR 0.28 (0.19–0.40)) and 12-month (OR 0.50 
(0.38–0.66)) mortality, and 30-day bleeding (OR 0.40 
(0.28–0.56)) compared with femoral artery access. Arte-
rial access site is an important variable to correct for 
considering the wealth of evidence showing that tran-
sradial PPCI is independently associated with improved 
clinical outcomes compared with transfemoral PPCI.16–24 
We had also adjusted for year of presentation, to try to 
correct for potential unrecorded confounders, such as 
progress with DES platforms and importantly, non-phar-
macological secondary prevention. Our key finding, that 
the third-generation P2Y12-receptor inhibitors were asso-
ciated with better outcomes compared with clopidogrel, 
was in keeping with their study.
Koshy et al25 compared 12-month mortality in prasugrel 
and clopidogrel, and reported that patients receiving pras-
ugrel had lower adjusted 12-month mortality compared 
with patients receiving clopidogrel. It is, however, 
important to note that patients who received prasugrel 
in their analysis were more likely to have undergone 
transradial PPCI compared with patients who received 
clopidogrel (78.0% vs 61.4%). However, in contrast to 
our study, choice of arterial access site was not included 
in their multivariable analysis. Postprocedural TIMI 3 
flow was also included in their Cox model, which we did 
not include in our regression model, as it was plausible 
that P2Y12-receptor inhibitors could influence post-PPCI 
microvascular function.26 Patient age and door-to-bal-
loon times also appeared different between our study 
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and Koshy et al’s, and higher rates of glycoprotein IIb/
IIIa inhibitor use was observed in both subgroups of their 
study compared with our study. Importantly, despite the 
difference in statistical analysis, along with differences in 
baseline and procedural characteristics, a similar asso-
ciation between prasugrel and survival was observed in 
both studies, with the additional finding of an inverse 
association between prasugrel and 12-month recurrent 
MI observed in our analysis.
There were several differences between the findings of 
our study and that of TRITON-TIMI 38.27 28 We observed 
lower 30-day and 12-month mortality in patients treated 
with prasugrel compared with clopidogrel. We also 
observed lower rates of recurrent MI within 12 months 
of index PPCI in patients receiving prasugrel compared 
with clopidogrel, which was in keeping with their find-
ings. There were important differences in baseline and 
procedural characteristics between the PPCI subgroup of 
TRITON-TIMI 38 and our study that could explain these 
differences. The patients in our study appeared older 
(median age 62 vs 59) and had higher prevalence of 
tobacco use (67.5% vs 45.0%), but a lower prevalence of 
diabetes mellitus (14.3% vs 16.8%), hypertension (38.0% 
vs 48.7%) and hypercholesterolaemia (32.1% vs 37.6%). 
The patients included in our study were also more likely 
to receive DESs (60.1% vs 28.5%), were predominantly 
anticoagulated with bivalirudin (95.5% vs 1.0%) and 
were less likely to receive glycoprotein IIb/IIIa inhibitor 
(85.3% vs 66.2%) compared with the patients in TRITON 
TIMI 38. Our analysis of 30-day bleeding was in keeping 
with this study, which also found no statistically signifi-
cant difference in bleeding at 30 days.
In a subgroup analysis from the PLATO investigators 
of patients with STEMI intended for management by 
PPCI,29 all-cause mortality reduction in patients treated 
with ticagrelor compared with patients treated with 
clopidogrel approached statistical significance (p=0.05) 
at 12 months, a finding that we did not observe in this 
study. The main statistically significant differences in 
outcomes were a reduction in vascular mortality, MI and 
stent thrombosis at 12 months for ticagrelor compared 
with clopidogrel. Conversely, an increased risk of stroke 
was noted in patients treated with ticagrelor. In our study, 
we found that patients treated with ticagrelor had lower 
rates of recurrent MI at 30 days and 12 months compared 
with patients treated with clopidogrel. We found that 
patients treated with ticagrelor did not have a higher rate 
of bleeding compared with patients treated with clopido-
grel, in keeping with the PLATO substudy analysis. There 
were, however, important differences in clinical character-
istics between the PLATO substudy and our study popu-
lation that could account for the differences observed. 
In the PLATO substudy, patients who received open-label 
clopidogrel prerandomisation were then given an addi-
tional 600 mg loading dose of clopidogrel on randomisa-
tion (if randomised to clopidogrel). The majority of their 
patients received BMSs instead of DESs, and procedural 
anticoagulation was mainly achieved with unfractionated 
heparin, rather than bivalirudin, with higher use of glyco-
protein IIb/IIIa inhibitor in comparison with our study 
population.
In our study, there were significant differences in 
baseline and procedural characteristics between the 
three groups of patients (table 1). There was a temporal 
change in the use of individual P2Y12-receptor inhibitors 
over the study period (figure 1). In 2009, the majority 
of patients undergoing PPCI in LGI received clopido-
grel, with the remainder receiving prasugrel. In 2010 
and 2011, the majority of patients received prasugrel 
and in 2013, the majority of patients received ticagrelor. 
During this period, there were changes in the rates of 
transradial PPCI (39.6% in 2009 vs 81.8% in 2013) and 
the use of DESs (41.3% in 2009 vs 82.2% in 2013). As 
a result of lower thresholds for accepting patients for 
PPCI, a higher proportion of patients in the ticagrelor 
cohort underwent PPCI for cardiogenic shock, which is 
traditionally regarded as a marker of poor prognosis.30 
There were also advances in secondary prevention over 
the study period, including an increased rate of implanta-
tion of primary-prevention implantable cardioverter-de-
fibrillator devices.31 These and other confounders, such 
as changes in clinical practice, improvements in operator 
proficiency and improvements in the PPCI pathway, could 
have all contributed to the differences in unadjusted 
outcomes. However, multivariable analysis, including 
adjustment for year of PPCI to adjust for unquantifiable 
time-dependent confounders, was undertaken to correct 
for major confounding factors.
lIMItatIons
As this was a single-centre observational study, our find-
ings might not reflect the broader population. However, 
our study demographics are comparable to those in 
the UK Myocardial Ischaemia National Audit Project 
(MINAP). Our practice and outcomes might not reflect 
those in other regions, as regional differences in STEMI 
management have been reported.32 We were unable to 
correct for Killip class. However, with this study being an 
‘all-comers’ study, we have no reason to believe that there 
would be statistically significant differences in Killip class 
between the groups. There have been many advances in 
procedural techniques and technologies over the years 
such that we were not able to correct for the generation 
of DES used in each subgroup, which potentially could 
have affected outcomes. However, we tried to correct 
for these by adjusting for the year of admission. As this 
was an observational study, the study populations were 
unmatched. However, multivariable analyses were under-
taken to adjust for major confounders. Perhaps most 
importantly we were unable to fully ascertain contin-
uation and/or switching of P2Y12-receptor inhibitors 
following discharge, but this limitation was also present 
in the only other comparable real-world studies.9 10 25 
Switching from ticagrelor was noted in PLATO due to 
dyspnoea, but also perhaps due to compliance with its 
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two times per day administration. However, in our study, 
differences in outcomes were observed in all three 
comparisons of P2Y12-receptor inhibitors, which should 
not have been observed if switching of P2Y12-receptor 
inhibitor therapy influenced differences in outcomes. 
Event rates in this study were low compared with PLATO 
or TRITON-TIMI 38 that involved larger numbers of 
patients, as under-reporting of adverse events is more 
likely in observational studies compared with RCTs, and 
therefore play of chance could not be excluded. We 
were also unable to obtain details of other changes to 
secondary prevention (aspirin, beta-adrenergic receptor 
blockers, ACE-inhibitors and statins) at 30 days and 12 
months. However, they were unlikely to be different 
across the groups as they were all part of guideline-indi-
cated care through the period of study. Finally, the find-
ings observed in this study should be hypothesis-gener-
ating, and an adequately powered RCT may be able to 
reveal differences in outcomes between P2Y12-receptor 
inhibitors that might inform future guidelines pertaining 
to optimal DAPT strategy following PPCI.
ConClusIon
In PPCI, treatment with prasugrel was independently 
associated with lower adjusted probabilities of 30-day 
and 12-month mortality, and 12-month MI compared 
with clopidogrel. Importantly, treatment with prasugrel 
was independently associated with lower adjusted 30-day 
mortality compared with ticagrelor. Although 30-day 
and 12-month MI were lower in patients treated with 
ticagrelor compared with clopidogrel, there were no 
significant differences in 30-day and 12-month mortality 
between patients treated with ticagrelor and clopidogrel. 
Overall, the third-generation P2Y12-receptor inhibitors 
were associated with lower adverse outcomes compared 
with clopidogrel, with no excess bleeding.
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